Sumitomo Pharma Co., Ltd.
4506
Rang in aandelen
#3139
Sumitomo Pharma Co., Ltd. is a global company involved in the creation,... Sumitomo Pharma Co., Ltd. is a global company involved in the creation, production, and sale of a variety of products, including human pharmaceuticals, food ingredients and additives, and veterinary medicines. Its operations span across Japan, North America, China, and other international territories. The company's pharmaceutical offerings address a broad spectrum of medical needs. These include treatments for conditions such as Parkinson's disease, depression, type 2 diabetes, systemic fungal infections, hypertension, pruritus, chronic obstructive pulmonary disease (COPD), angina pectoris, and arrhythmia. Additionally, they manufacture atypical antipsychotics, antiepileptics, carbapenem antibiotics, gastrointestinal products, and specialized medications for Anderson-Fabry disease. Beyond healthcare, Sumitomo Pharma provides food components and enhancement agents like polysaccharides, along with savory flavorings such as soups and bouillons. The company also supplies chemical raw materials, which encompass pharmaceutical excipients, components for personal care products, substances used in coatings and industrial applications, and electronic materials. Moreover, it produces veterinary therapeutic solutions designed for domestic pets, specifically dogs and cats, as well as for various farm animals, including cattle, swine, poultry, horses, and cultivated fish. To drive innovation, Sumitomo Pharma fosters partnerships with several organizations. These collaborators include Healios K.K., Keio University, RIKEN, the Center for iPS Cell Research and Application, Kyoto University, and Aikomi Co., Ltd. The company also maintains a joint development agreement with SanBio Company Limited, a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd., and a strategic alliance with Roivant Sciences Ltd. Originally established in 1897, the company, headquartered in Osaka, Japan, was known as Sumitomo Dainippon Pharma Co., Ltd. until it adopted its current name, Sumitomo Pharma Co., Ltd., in April 2022. It functions as a subsidiary of Sumitomo Chemical Company, Limited.
Aandeelprijs
$12.86
Marktkapitalisatie
$5.77B
Verandering (1 dag)
4.48%
Verandering (1 jaar)
15.98%
Land
JP
Handel Sumitomo Pharma Co., Ltd. (4506)
Categorie
Healthcare
Aantal uitstaande aandelen voor Sumitomo Pharma Co., Ltd. (4506)
Aantal uitstaande aandelen per June 2026: 435.63M
Volgens de laatste financiële rapporten en de aandelenkoers van Sumitomo Pharma Co., Ltd. bedraagt het huidige aantal uitstaande aandelen 435.63M. Aan het einde van March 2024 had het bedrijf 397.29M uitstaande aandelen. Het aantal uitstaande aandelen wordt meestal beïnvloed door aandelensplitsingen en terugkoop van aandelen.
Geschiedenis van uitstaande aandelen van Sumitomo Pharma Co., Ltd. (4506) van 2005 tot 2026
Uitstaande aandelen aan het einde van elk jaar
| Jaar | Uitstaande aandelen | Wijzigen |
|---|---|---|
| 2026 (TTM) | 435.63M | 9.65% |
| 2025 | 397.29M | 0.00% |
| 2024 | 397.29M | 0.00% |
| 2023 | 397.29M | 0.00% |
| 2022 | 397.29M | 0.00% |
| 2021 | 397.29M | 0.00% |
| 2020 | 397.30M | 0.00% |
| 2019 | 397.30M | 0.00% |
| 2018 | 397.30M | 0.00% |
| 2017 | 397.30M | 0.00% |
| 2016 | 397.30M | 0.00% |
| 2015 | 397.31M | 0.00% |
| 2014 | 397.31M | 0.00% |
| 2013 | 397.31M | 0.00% |
| 2012 | 397.31M | 0.00% |
| 2011 | 397.31M | 0.00% |
| 2010 | 397.32M | -0.01% |
| 2009 | 397.36M | -0.02% |
| 2008 | 397.45M | -0.01% |
| 2007 | 397.50M | 41.46% |
| 2006 | 280.99M | 70.18% |
| 2005 | 165.11M | 0.00% |
Uitstaande aandelen van vergelijkbare bedrijven of concurrenten
| Bedrijf | Uitstaande aandelen | Verschil | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 2.40B | 450.78% |
IN
|
